Your browser doesn't support javascript.
loading
Quantification of Immune Variables from Liquid Biopsy in Breast Cancer Patients Links Vδ2+ γδ T Cell Alterations with Lymph Node Invasion.
Fattori, Stéphane; Gorvel, Laurent; Granjeaud, Samuel; Rochigneux, Philippe; Rouvière, Marie-Sarah; Ben Amara, Amira; Boucherit, Nicolas; Paul, Magali; Dauplat, Marie Mélanie; Thomassin-Piana, Jeanne; Paciencia-Gros, Maria; Avenin, Morgan; Pakradouni, Jihane; Barrou, Julien; Charafe-Jauffret, Emmanuelle; Houvenaeghel, Gilles; Lambaudie, Eric; Bertucci, François; Goncalves, Anthony; Tarpin, Carole; Nunès, Jacques A; Devillier, Raynier; Chretien, Anne-Sophie; Olive, Daniel.
Afiliação
  • Fattori S; Team Immunity and Cancer, Centre de Recherche en Cancérologie de Marseille (CRCM), Inserm, U1068, CNRS, UMR7258, Institut Paoli-Calmettes, Aix-Marseille University, UM 105, 13009 Marseille, France.
  • Gorvel L; Cancer Immunomonitoring Platform, Centre de Recherche en Cancérologie de Marseille (CRCM), Inserm, U1068, CNRS, UMR7258, Institut Paoli-Calmettes, 13009 Marseille, France.
  • Granjeaud S; Team Immunity and Cancer, Centre de Recherche en Cancérologie de Marseille (CRCM), Inserm, U1068, CNRS, UMR7258, Institut Paoli-Calmettes, Aix-Marseille University, UM 105, 13009 Marseille, France.
  • Rochigneux P; Cancer Immunomonitoring Platform, Centre de Recherche en Cancérologie de Marseille (CRCM), Inserm, U1068, CNRS, UMR7258, Institut Paoli-Calmettes, 13009 Marseille, France.
  • Rouvière MS; Systems Biology Platform, Centre de Recherche en Cancérologie de Marseille (CRCM), Inserm, U1068, CNRS, UMR7258, Institut Paoli-Calmettes, Aix-Marseille University, UM 105, 13009 Marseille, France.
  • Ben Amara A; Team Immunity and Cancer, Centre de Recherche en Cancérologie de Marseille (CRCM), Inserm, U1068, CNRS, UMR7258, Institut Paoli-Calmettes, Aix-Marseille University, UM 105, 13009 Marseille, France.
  • Boucherit N; Cancer Immunomonitoring Platform, Centre de Recherche en Cancérologie de Marseille (CRCM), Inserm, U1068, CNRS, UMR7258, Institut Paoli-Calmettes, 13009 Marseille, France.
  • Paul M; Department of Medical Oncology, Institut Paoli-Calmettes, 13009 Marseille, France.
  • Dauplat MM; Team Immunity and Cancer, Centre de Recherche en Cancérologie de Marseille (CRCM), Inserm, U1068, CNRS, UMR7258, Institut Paoli-Calmettes, Aix-Marseille University, UM 105, 13009 Marseille, France.
  • Thomassin-Piana J; Cancer Immunomonitoring Platform, Centre de Recherche en Cancérologie de Marseille (CRCM), Inserm, U1068, CNRS, UMR7258, Institut Paoli-Calmettes, 13009 Marseille, France.
  • Paciencia-Gros M; Team Immunity and Cancer, Centre de Recherche en Cancérologie de Marseille (CRCM), Inserm, U1068, CNRS, UMR7258, Institut Paoli-Calmettes, Aix-Marseille University, UM 105, 13009 Marseille, France.
  • Avenin M; Cancer Immunomonitoring Platform, Centre de Recherche en Cancérologie de Marseille (CRCM), Inserm, U1068, CNRS, UMR7258, Institut Paoli-Calmettes, 13009 Marseille, France.
  • Pakradouni J; Team Immunity and Cancer, Centre de Recherche en Cancérologie de Marseille (CRCM), Inserm, U1068, CNRS, UMR7258, Institut Paoli-Calmettes, Aix-Marseille University, UM 105, 13009 Marseille, France.
  • Barrou J; Cancer Immunomonitoring Platform, Centre de Recherche en Cancérologie de Marseille (CRCM), Inserm, U1068, CNRS, UMR7258, Institut Paoli-Calmettes, 13009 Marseille, France.
  • Charafe-Jauffret E; Team Immunity and Cancer, Centre de Recherche en Cancérologie de Marseille (CRCM), Inserm, U1068, CNRS, UMR7258, Institut Paoli-Calmettes, Aix-Marseille University, UM 105, 13009 Marseille, France.
  • Houvenaeghel G; Cancer Immunomonitoring Platform, Centre de Recherche en Cancérologie de Marseille (CRCM), Inserm, U1068, CNRS, UMR7258, Institut Paoli-Calmettes, 13009 Marseille, France.
  • Lambaudie E; Department of Pathology, Institut Paoli-Calmettes, 13009 Marseille, France.
  • Bertucci F; Department of Pathology, Institut Paoli-Calmettes, 13009 Marseille, France.
  • Goncalves A; Department of Pathology, Institut Paoli-Calmettes, 13009 Marseille, France.
  • Tarpin C; Department of Pathology, Institut Paoli-Calmettes, 13009 Marseille, France.
  • Nunès JA; Department of Clinical Research and Innovations, Institut Paoli-Calmettes, 13009 Marseille, France.
  • Devillier R; Department of Surgical Oncology, Institut Paoli-Calmettes, 13009 Marseille, France.
  • Chretien AS; Department of Pathology, Institut Paoli-Calmettes, 13009 Marseille, France.
  • Olive D; Team Epithelial Stem Cells and Cancer, Centre de Recherche en Cancérologie de Marseille (CRCM), Inserm, U1068, CNRS, UMR7258, Institut Paoli-Calmettes, Aix-Marseille University, UM 105, 13009 Marseille, France.
Cancers (Basel) ; 13(3)2021 Jan 25.
Article em En | MEDLINE | ID: mdl-33503843
ABSTRACT
The rationale for therapeutic targeting of Vδ2+ γδ T cells in breast cancer is strongly supported by in vitro and murine preclinical investigations, characterizing them as potent breast tumor cell killers and source of Th1-related cytokines, backing cytotoxic αß T cells. Nonetheless, insights regarding Vδ2+ γδ T cell phenotypic alterations in human breast cancers are still lacking. This paucity of information is partly due to the challenging scarcity of these cells in surgical specimens. αß T cell phenotypic alterations occurring in the tumor bed are detectable in the periphery and correlate with adverse clinical outcomes. Thus, we sought to determine through an exploratory study whether Vδ2+ γδ T cells phenotypic changes can be detected within breast cancer patients' peripheral blood, along with association with tumor progression. By using mass cytometry, we quantified 130 immune variables from untreated breast cancer patients' peripheral blood. Supervised analyses and dimensionality reduction algorithms evidenced circulating Vδ2+ γδ T cell phenotypic alterations already established at diagnosis. Foremost, terminally differentiated Vδ2+ γδ T cells displaying phenotypes of exhausted senescent T cells associated with lymph node involvement. Thereby, our results support Vδ2+ γδ T cells implication in breast cancer pathogenesis and progression, besides shedding light on liquid biopsies to monitor surrogate markers of tumor-infiltrating Vδ2+ γδ T cell antitumor activity.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Revista: Cancers (Basel) Ano de publicação: 2021 Tipo de documento: Article País de afiliação: França

Texto completo: 1 Base de dados: MEDLINE Idioma: En Revista: Cancers (Basel) Ano de publicação: 2021 Tipo de documento: Article País de afiliação: França